Rezafungin Acetate

Phase 3Small molecule

CCidara Therapeutics Inc.

Rezafungin Acetate is one of 81 small molecule programs targeting Aspergillosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AspergillosisActive, not recruiting

CandidiasisActive, not recruiting

PneumoniaActive, not recruiting

AspergillosisPhase 2

Active, not recruiting

CandidiasisPhase 3

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Rezafungin Acetate

CCidara Therapeutics Inc.

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Jakafi

Incyte

Preclinical

1 4

Primaquine

Sanofi

Preclinical

1 5

Acanya

Pfizer

Preclinical

1 6

Prevacid

Takeda

Preclinical

1 7

Innohep

Alnylam Pharmaceuticals

Preclinical

1 8

Avlosulfon

AAlmirall, S.A.

Preclinical

4 9

Neutrexin

WWest Japan Thoracic Oncology Group

Advil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Aspergillosis

NCT06794554

Clinical

Trials by Indication[1]

Age1 trial

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

Terminated·MMundipharma Research Limited·Phase 1·NCT05534529·32 enrolled

Aspergillosis1 trial

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

Recruiting·MMundipharma Research Limited·Phase 2·NCT06794554·60 enrolled

Invasive Fungal Disease1 trial

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, not recruiting·MMundipharma Research Limited·Phase 3·NCT04368559·602 enrolled

Pneumonia1 trial

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Recruiting·MMundipharma Research Limited·Phase 2·NCT05835479·50 enrolled

Candidiasis1 trial

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Completed·CCidara Therapeutics Inc.·Phase 3·NCT03667690·199 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Rezafungin Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rezafungin Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rezafungin Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cidara Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCidara Therapeutics Inc.

Rezafungin Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Age1 trial

Aspergillosis1 trial

Invasive Fungal Disease1 trial

Pneumonia1 trial

Candidiasis1 trial

References

Drug Info

Quick Facts

Related News